Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04886258 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis
A Phase 2 study of Symptomatic Knee Osteoarthritis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
- 20
- Study locations
NCT04886258: Completed Phase 2 study of Symptomatic Knee Osteoarthritis, sponsored by Novartis Pharmaceuticals.
NCT04886258 is a Phase 2 study of Symptomatic Knee Osteoarthritis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 115 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04886258, a Phase 2 study of Symptomatic Knee Osteoarthritis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.
Primary Outcome
The KOOS questionnaire is a commonly used instrument to assess the patient's perception about their knee and associated problems. The original KOOS consists of 5 subscales. One of those is the pain frequency/severity during functional activities consisting of 9 questions with a recall of 7 days. Each question has 5 standardized answer options with a score from 0 to 4. A normalized score (100 indicating no pain and 0 indicating extreme pain) is calculated for each subscale. Change from baseline i
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DFV890
Study Locations (20)
Other
- Novartis Investigative Site - San Miguel de Tucumán
- Novartis Investigative Site - Nový Jičín
- Novartis Investigative Site - Prague
- Novartis Investigative Site - Uherské Hradiště
- Novartis Investigative Site - Bad Doberan
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Leipzig
Florida
- IRIS Research and Development - Plantation
- Conquest Research - Winter Park
Arizona
- ARENSIA Explor Med Res Clinic - Phoenix
California
- TriWest Reserach Associates - El Cajon
Colorado
- Skylight Health Res Inc Color Spr - Colorado Springs
Georgia
- Ctr for Adv Research and Education - Gainesville
Illinois
- Northwestern University - Chicago
Buenos Aires
- Novartis Investigative Site - CABA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 2 |
What the finished NCT04886258 record still lists
NCT04886258 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Symptomatic Knee Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04886258 names 20 study sites across 11 states, led by Other, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04886258 about?
NCT04886258 is a clinical study titled "Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis". This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.
What is the current status of trial NCT04886258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2021-09-20. Estimated completion is 2024-12-23.
What conditions does trial NCT04886258 study?
This clinical trial studies the following conditions: Symptomatic Knee Osteoarthritis.
What interventions are being tested in trial NCT04886258?
The interventions under investigation include: Placebo (DRUG), DFV890 (DRUG).
Who is sponsoring clinical trial NCT04886258?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04886258 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04886258's enrollment target sits among peer trials
115 626th of 2000 higher than 1,374 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI